Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ista acquires rights to conjunctivitis drug
Under the terms of the agreement, Ista will pay Senju an upfront payment and aggregate development and approval milestones of approximately $6 million. The licensed drug is an
Under the terms of the agreement, Ista will pay Senju an upfront payment and aggregate development and approval milestones of approximately $6 million. The licensed drug is an
The company reached the agreement under the special protocol assessment process (SPA). The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the
The phase II study in advanced non-small cell lung cancer (NSCLC) is a randomized trial that is expected to involve over 20 centers in the US and Europe
The open-label trial was conducted in Europe in collaboration with Aeterna Zentaris’ partner Spectrum Pharmaceuticals. Originally designed for 48 patients, the trial was extended to 64 patients where
Keppra injection is an alternative for patients when oral administration is temporarily not feasible. It must be diluted prior to use and administered as a 15-minute intravenous infusion.
XL647 is an orally bioavailable small molecule inhibitor of the HER2, EGF, VEGF and EphB4 receptor tyrosine kinases (RTKs). Although these individual RTKs are targets for currently approved
Chantix, the first new prescription aid to smoking cessation treatment approved by the FDA in nearly a decade, was approved in May 2006. According to the company, there
Dacogen was previously approved by the FDA in May 2006 for the treatment of patients with myelodysplastic syndromes (MDS), a group of blood disorders which may lead to
This global opinion, published in Current Medical Research and Opinion, declares the consensus findings of The International Aromatase Inhibitor (AI) Expert Panel, composed of 24 breast cancer clinicians
Barr’s Alprazolam extended-release tablets will compete in a market that had total annual sales of approximately $83 million for the 12 months ending May 2006, according to data